News

Ribo submits RBD1119 Phase 2 application to EMA for coronary artery disease, targeting residual thrombotic risk in stable CAD...

Zanidatamab doubles survival in HER2-positive gastric cancer trial, achieving 29.7 months median OS versus 15.8 months with trastuzumab in...

TG Therapeutics' ublituximab shows bioequivalent exposure in single-dose trial, potentially simplifying MS treatment initiation with reduced clinic visits.

Zumilokibart achieves EASI-75 target in Phase 2 atopic dermatitis trial with fewer injections than dupilumab and lower conjunctivitis rates.

Novartis presents eGFR slope data for IgAN kidney disease treatments at ERA 2026, comparing complement inhibition and endothelin receptor...

FDA Approves DECNUPAZ for blastic plasmacytoid dendritic cell neoplasm, achieving 69.7% composite complete response in newly diagnosed patients.

Aktis Oncology's AKY-2519 demonstrates lower salivary gland toxicity compared to approved PSMA agents in first-in-human dosimetry study.

TaiMed completes Phase 2b enrollment for TMB-365/380, a dual antibody HIV therapy dosed every two months without pre-screening requirements.

Tedopi Plus Pembrolizumab reduces progression or death risk by 47% versus supportive care in platinum-sensitive recurrent ovarian cancer.

Idefirix kidney transplant study reports 90% graft survival at one year in highly sensitized patients, supporting Hansa's bid for...